PARP inhibitor re‑sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis
Jie Wu(University of Oklahoma Health Sciences Center), Chenjiao Yao(Third Xiangya Hospital)
Cited by 17
Related Papers
Phosphotyrosines 627 and 659 of Gab1 Constitute a Bisphosphoryl Tyrosine-based Activation Motif (BTAM) Conferring Binding and Activation of SHP2
|Journal of Biological Chemistry|2001|167
Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma
|British Journal of Cancer|2015|81
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib
|npj Precision Oncology|2021|49
Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors
|Molecular Cancer Therapeutics|2023|14
Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy
|RSC Medicinal Chemistry|2025|1